tion, this technique is limited in its ability to capture all the inflammation that may be present in the esophagus since it samples a small fraction of the total circumferential and longitudinal mucosa. This is particularly important limitation since EoE is a panesophageal disease.
Other metrics have relied on the appearance of the mucosa with respect to the amount of exudate and edema and degree of furrowing, rings and stricture formation [4] . In addition, assessments of esophageal wall compliance with EndoFLIP and contractions with high-resolution manometry have provided real-time assessment of esophageal function [5, 6] . These represent important steps forward in the analysis of response to treatments, but are relatively invasive techniques that require specialized equipment and interpretation.
While the current standard of care dictates that counting of eosinophils is the gold standard to monitor inflammation activity, other methods that have sought to improve on this analysis include development of scoring systems based on immunohistochemical staining for eosinophil granule proteins and molecular-based panels. Together, they represent excellent metrics to further understand pathogenetic mechanisms and response to treatments, but again they require endoscopic procedures [7] [8] [9] .
Biomarkers and Non-/Minimally Invasive Measurement Techniques
Based on these concerns and limitations, the search for, and validation of, biomarkers that reflect mucosal inflammation in patients with EoE that can be captured in a non-/minimally invasive fashion continues. Below is a summary of the minimally invasive methods and biomarkers used to assess EoE disease activity.
Peripheral Blood Eosinophils
A number of studies have focused on determining whether patients with EoE also demonstrated evidence of peripheral eosinophilia [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . This was based on the rationale that either patients with EoE may have elevated systemic levels of eosinopoietic or Th2 cytokines, or that patients who were experiencing a flare would have elevated peripheral eosinophils that could be captured during their migration from the bone marrow to the esophageal mucosa. Comparisons of these studies are hampered by the fact that threshold levels defining peripheral eosinophilia vary from study to study, subject populations may include atopic patients or not, and documentation of medication use that may influence counts is inconsistent. Overall, the majority, but not all, of these studies show that peripheral eosinophil levels can increase during active disease, but whether this reflects mucosal inflammation, or other atopic disease activity in general, is less certain [48, 49] . Researchers have addressed this in a number of ways. First, investigators have attempted to tease apart peripheral eosinophilia from other factors by comparing atopic features in EoE subjects with asthma to another group who only had asthma [22] . Atopic features included peripheral eosinophilia, history of concomitant allergic diseases, family history of eosinophils and gender. They determined that peripheral eosinophilia was the most highly significant feature distinguishing patients with EoE and asthma from those only with asthma. In another study, investigators used logistic regression analysis of clinical features and determined that the combination of peripheral eosinophilia, a history of food impaction and proton pump inhibitor refractory heartburn was able to distinguish EoE from gastroesophageal reflux disease [23] . Another study examined whether phenotypic analysis of eosinophil surface markers could distinguish treated from untreated disease. Elevated levels of surface CD66 intracellular phospho-STAT1, and phospho-STAT6 were able to differentiate children with active disease from treated and healthy controls [24] . Finally, a prospective study of 47 children revealed that absolute eosinophil count, eosinophilderived neurotoxin levels and eotaxin-3 levels together correlated with esophageal inflammation [25] .
Eosinophil granule proteins were measured before and after anti-IL-5 antibody treatment, demonstrating significant declines in eosinophilic cationic protein and eosinophil-derived neurotoxin followed up to 13 weeks of treatment [14] . In contrast, another study studying oral viscous budesonide in adults with EoE found no correlation of serum eosinophilic cationic protein with disease activity [14] . Finally, one study determined that eosinophil-derived neurotoxin levels provided a sustained decrease following treatment in 66 children with EoE [26] . Thus, while there appears to be a correlation of peripheral eosinophils with active inflammation, the ability for this metric alone to track disease activity is limited.
Cytokines
With advanced understanding of the molecular mechanisms of EoE, a number of studies have sought to determine whether EoE-related cytokines, including IL-5, IL-13, IL-15, CCL5, GM-CSF and others, were increased in the peripheral circulation [27] [28] [29] . In this regard, it is likely that these cytokines play a role in creation of an immunomicromilieu that is conducive to the development to of mucosal eosinophilia. The question of whether the measurement of peripheral cytokines will be reflective of the esophageal mucosa has led to a series of studies to assess levels of these potential surrogate markers in EoE patients. These studies have either measured Th2 cytokines in plasma of EoE patients or measured these cytokines in the supernatants of peripheral leukocytes taken from these patients.
With respect to the former studies, peripheral cytokines were measured in 10 EoE adults and 8 normal controls [28] . In this series, most of the EoE subjects were not undergoing treatment, and results showed that IL-2, IL-3, IL-5 and RANTES were greater than in the controls. Therapeutic studies targeting IL-5 have revealed a lack of consistency in elevated levels during active disease and/or decreased levels following treatment [30] [31] [32] [33] [34] [35] . Straumann et al. [14] measured eotaxin before and after anti-IL-5 antibody treatment and found that levels increased in the treatment group and that there was no change in the placebo. In another study, these same investigators measured thymus and activationregulated chemokine levels before and after treatment and found a correlation of these peripheral measurements with mucosal eosinophilia [36] . Mishra and colleagues [29] determined that serum levels of IL-15 were significantly increased in the peripheral blood of actively inflamed EoE patients and that these levels decreased following diet restriction and topical steroid treatment. Other therapeutic studies targeting IL-5 have revealed a lack of consistency in either identifying elevated levels during active disease or sustained decreased levels following treatment [30] [31] [32] [33] [34] [35] . Finally, cytokine levels from normal (n = 12) and EoE subjects with active inflammation (n = 13) were quantified using a multiplex assay containing 84 cytokines [37] . Of these, IL-13, IL-4, IL-6, IL-5, CD40L, IL-12p70 and EGF levels were significantly altered in EoE compared with normal. When these results were applied to another group of subjects with active and inactive disease, no correlations were seen.
With respect to analyses of peripheral leukocyte stimulation assays, the most recent of these studies demonstrated that invariant natural killer cells stimulated with α-galactosylceramide and milk allergens release elevated levels of IL-4 and IL-13 [38] . While this intriguing result may replicate the in vivo microenvironment, these types of studies are hampered by variability in experimental conditions, thus preventing translation of their results to clinical utility.
Taken together, these results suggest that peripheral cytokine measurements do not consistently characterize the esophageal eosinophil levels or disease activity. In addition, analysis of peripheral cytokines, like measurements of peripheral eosinophil levels, are complicated by the confounding influence of concomitant allergic diseases and identification of validated threshold levels.
Exhaled Nitric Oxide
Fractionated exhaled nitric oxide (Fe NO ) has been used to assess eosinophil-predominant asthma and other atopic disorders. Since EoE is characterized by eosinophilia and basic studies suggest a link to pulmonary eosinophilia, Fe NO was measured in a prospective study of 11 nonasthmatic subjects with active esophagitis before and after treatment [39] . Five patients responded histologically to topical steroids; while patients experienced a decline in Fe NO , this difference did not reach statistical significance. There was a significant correlation between Fe NO and symptom scores in responders. Further work will be needed to fully assess the potential utility of this test in monitoring EoE disease activity.
Barium Esophagram
Initial and subsequent descriptions of EoE showed luminal narrowing, isolated strictures and Schatzki rings to be key features of this disease. Over a quarter of a century later, barium esophagram has reemerged as a potential tool to assess pediatric subjects with EoE [40] [41] [42] [43] [44] . Esophagrams provide a measure of motility, mucosal irregularities and stricture formation. A retrospective analysis of 112 studies performed within 30 days of the diagnosis revealed that 52% were normal, but a minority showed findings including stricture (11%), rings (7%) and small-caliber esophagus (5%) [45] . One prospective study used the minimal and maximal esophageal diameter (ED min and ED max , respectively) determined by esophagram as a therapeutic outcome [46] . Eleven adult subjects were treated for 6 weeks with topical steroids and had esophagrams performed before and after treatment. Baseline analysis revealed that the ED max was decreased in 50% of the EoE subjects compared to the healthy volunteer subjects. There were no statistically different changes in the ED min or ED max following treatment in the 11 patients, but in those EoE subjects with an initially abnormal esophagram, significant improvement was observed. As with Fe NO , additional studies will be needed to assess this as a valuable metric for following disease activity.
Luminal Secretions
As with other luminal diseases, inflammatory mediators may be released into the cavity and reflect disease activity, e.g. sampling for eosinophils in the bronchoalveoloar lavage fluid from patients with asthma to monitor for disease activity. With respect to EoE, we have assessed the luminal inflammatory contents of EoE patient's esophagus with the Enterotest TM , a string-based technology and termed this the esophageal string test [47] . The Enterotest technology was developed and suc- cessfully implemented in the 1970s to capture duodenal parasites. It consists of a weighted gelatin capsule filled with a nylon string. When the capsule is swallowed, the trailing string is taped to the cheek while the rest of the string is deployed into the esophagus, stomach and small intestine. The delivery capsule is released from the string, thus leaving the trailing string to capture esophageal luminal contents. We studied 42 subjects with the esophageal string test and were able to demonstrate that it was able to capture eosinophil granule proteins from the esophageal lumen and that concentrations of these proteins correlated significantly with eosinophil counts and protein concentrations found in mucosal biopsies. In addition, eosinophil-derived granule protein levels correlated significantly with disease activity. These results provide evidence that this methodology may be beneficial to monitor inflammation and disease activity .
When to Monitor?
This question continues to haunt patients and clinicians alike. Clearly, assessment of mucosal inflammation is necessary to make a diagnosis of EoE. After this initial assessment, however, the rationale for continuing monitoring still lies in the identification of meaningful clinical inflammation and complications such as strictures. While malignancy has not been reported in patients with EoE, some concerns about transformation of chronic inflammation to Barrett's esophagus still exist.
In this light, it is our practice to perform a mucosal biopsy after symptoms have improved and following 8-12 weeks of medical or diet treatment. Following this second endoscopy, a number of approaches toward following disease activity have been promoted. With respect to diet therapy, some advocate mucosal biopsy after each food has been added to the diet, some perform a biopsy after several foods and some do not perform another biopsy when the patient is doing well clinically. Since symptoms do not always match esophageal inflammation, a case can be made for any of these scenarios, but the risks and benefits of each option need to be carefully discussed with the patient and family.
'Surveillance' of the esophageal mucosa in patients with EoE following establishment of histopathological remission is a subject of even more controversy. After an effective diet is determined or medical treatment defined, some perform yearly assessments of the mucosa to insure the continued success of treatment and/or determine whether complications have developed. Another approach is to not perform another endoscopy when the patient is asymptomatic and treatments are well tolerated. This approach may involve some risk of not documenting the natural history of the disease.
Finally, assessment of the mucosa may be dictated when a previously stable patient becomes symptomatic somewhat acutely. The differential diagnosis includes recurrent EoE due to encountering an allergen, viral/fungal infection, lack of adherence to treatment or concomitant reflux disease. If these are addressed, or if patients remain symptomatic, monitoring of the mucosa may be indicated.
Conclusion
Each of these biomarkers and scenarios is presented so that clinicians can consider the best approaches for their patients. In addition, as novel therapeutics continue to be developed and studied, new techniques and biomarkers will need to be considered. Future studies documenting the impact of novel biomarkers and assessment techniques that reflect tissue eosinophilia and/or disease activity will refine the overall care of EoE patients.
